Curated News
By: NewsRamp Editorial Staff
October 07, 2025
AXIM & JK Medical Partner to Bring Rapid Eye Diagnostics to Latin America
TLDR
- AXIM Biotechnologies gains exclusive market access across seven Latin American countries through JK Medical, expanding its diagnostic test reach and competitive position.
- AXIM's TearScan tests use lactoferrin and IgE biomarkers to differentiate between aqueous-deficient dry eye, allergic conjunctivitis, and evaporative dry eye through rapid point-of-care analysis.
- This partnership expands access to rapid ocular diagnostics across Latin America, helping millions receive faster, more accurate diagnoses for dry eye and allergy conditions.
- AXIM's TearScan tests can diagnose dry eye and ocular allergies in minutes using tear biomarkers, revolutionizing how eye conditions are identified in clinical settings.
Impact - Why it Matters
This partnership directly impacts millions of Latin Americans suffering from dry eye disease and ocular allergies by making advanced diagnostic tools more accessible. For patients, this means faster, more accurate diagnoses and targeted treatments that address the root cause of their eye conditions rather than just managing symptoms. For healthcare providers, it represents a significant advancement in clinical capabilities, enabling differential diagnosis at the point of care and reducing the time between initial consultation and effective treatment. Given that dry eye affects approximately 350 million people globally with tens of millions in Latin America alone, this collaboration addresses a substantial unmet medical need in a region where specialized diagnostic tools have traditionally been limited. The availability of these rapid tests could transform standard of care for ocular conditions that significantly impact quality of life and productivity.
Summary
AXIM Biotechnologies, Inc. (OTC: AXIM), a pioneering diagnostics company specializing in rapid, point-of-care ophthalmic testing, has announced a landmark exclusive license and distribution agreement with JK Medical, Inc. that will bring innovative ocular diagnostics to seven Latin American countries: Brazil, Chile, Peru, Argentina, Mexico, Ecuador, and Colombia. This strategic partnership pairs AXIM's groundbreaking TearScan® diagnostic portfolio with JK Medical's established regional market access and commercialization capabilities, creating a powerful alliance to transform eye care delivery across the continent. The agreement specifically covers AXIM's TearScan® Lactoferrin Diagnostic Test for aiding in the diagnosis of aqueous-deficient Dry Eye Disease (DED) and the TearScan® IgE Diagnostic Test for aiding in the diagnosis of allergic conjunctivitis, providing clinicians with essential tools for differential diagnosis at the point of care.
The collaboration represents a significant advancement in addressing the substantial unmet need in dry eye diagnosis across Latin America, where tens of millions suffer from DED among the estimated 350 million affected worldwide. Under the four-year exclusivity arrangement, JK Medical will lead distribution, education, and onboarding efforts while AXIM provides product supply, training, and technical support. The partnership includes immediate commercialization in Chile, with exclusivity commencing once regulatory approval is obtained in two of the seven countries. Both companies emphasize the importance of this collaboration in supporting eye-care professionals with objective biomarkers that complement clinical evaluation, enabling faster, more accurate diagnoses and targeted treatment decisions for conditions that have traditionally been challenging to differentiate through visual inspection alone.
The TearScan® portfolio stands as the only point-of-care solution that enables eye-care professionals to identify whether a patient has aqueous-deficient DED, allergic conjunctivitis, or a combination of these conditions, making correct differential diagnosis possible at the first visit. By testing for Lactoferrin levels, clinicians can determine if a patient has ADDE when levels are below normal, while normal Lactoferrin levels prompt IgE testing for allergic conjunctivitis. This systematic approach allows for process-of-elimination diagnosis and indicates when additional testing for evaporative DED may be necessary. These rapid, inexpensive tests save valuable chair time while giving patients faster, more accurate answers, positioning them as primary front-line tools in dry eye and ocular allergy care throughout Latin America's growing healthcare markets.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, AXIM & JK Medical Partner to Bring Rapid Eye Diagnostics to Latin America
